Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index; 42 of the 69 sources its claims cite were checked for support.

The double-edged sword of regulatory T cells in MASLD: from inflammation control to fibrosis promotion

Open access
Lee, So Eun, Jo, Min Gi, Park, Sang Won, Kim, Hye Jung, Yun, Seung Pil, Kim, Jong-Won · 2026 · Animal Cells and Systems

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its advanced inflammatory subtype, metabolic dysfunction-associated steatohepatitis (MASH), are becoming increasingly prevalent liver disorders driven by complex interactions between metabolic stress, immune dysregulation, and fibrotic remodeling. Regulatory T cells (Tregs), traditionally recognized for their immunosuppressive functions, have emerged as key modulators of hepatic inflammation, fibrosis, and systemic metabolic balance. While Tregs can suppress pro-inflammatory immune responses and mitigate liver injury, accumulating evidence highlights their paradoxical roles in liver fibrosis, including the promotion of hepatic stellate cell activation and profibrotic remodeling. This review critically examines the dual and context-dependent roles of Tregs in MASLD and MASH, emphasizing implications for therapeutic intervention. Additionally, we discuss current preclinical strategies aimed at modulating Treg abundance and function, highlighting the challenges and opportunities associated with developing stage-specific therapeutic approaches that consider not only local hepatic effects but also potential systemic metabolic consequences.

Overview

CoChat Summary

## TL;DR

This is a narrative review of how regulatory T cells (Tregs) can both protect against inflammation and also promote fibrosis in MASLD/MASH. The paper argues that Treg-targeted therapy will likely need to be stage-specific because boosting Tregs may help early disease but worsen fibrosis or tumor-promoting contexts later.

## Key findings

  • Tregs are presented as immunosuppressive cells that can limit hepatic inflammation in MASLD/MASH; Treg depletion worsened hepatic inflammation in MASLD, and restoring the Th17/Treg balance is proposed as a therapeutic direction.
  • The paper emphasizes a paradoxical fibrotic role: Tregs can promote hepatic stellate cell (HSC) activation through TGF-β-dependent signaling and IL-8 induction, and a subset of Tregs producing amphiregulin (AREG) drives profibrotic programs.
  • In one cited diet-induced MASH study, Treg-specific deletion of Areg attenuated fibrosis in multiple models without significantly changing hepatic lipid accumulation or inflammation; mice lacking Egfr specifically on HSCs were protected from both fibrosis and glucose dysregulation.
  • The review notes that at least one model linked the ATF4–integrin αvβ8 axis in hepatic Tregs to fibrosis; blockade of integrin αvβ8 reduced active TGF-β and attenuated fibrosis in mice.

## Methods

  • Not stated in the paper.
  • The article is a review that synthesizes prior murine and human studies on Treg biology in MASLD/MASH, rather than presenting a new experimental cohort or trial.
  • Its main analysis is a narrative, mechanism-focused interpretation of published findings on Treg phenotypes, immunometabolic regulation, and therapeutic strategies.

## Limitations

  • The paper states that the roles of Tregs in MASLD and MASH “remain unclear,” and that no distinct liver-specific Treg phenotype has been conclusively identified.
  • It also states that direct experimental evidence for some proposed mechanisms is limited, including the FOXO–Treg axis in MASLD.
  • Evident from the text: this is a review of preclinical and prior human studies, so its conclusions depend on heterogeneous external studies rather than new primary data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1080/19768354.2026.2630463

Cites

121 of 121 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Mechanisms of immunosuppression mediated by Tregs. Tregs suppress immune responses via multiple mechanisms and maintain tissue homeostasis. (A) CTLA4-mediated suppression: Treg-expressed CTLA-4 inhibits DC co-stimulation by reducing CD80/CD86 availability, thereby suppressing Teff activation. (B) IDO induction by DC: CTLA-4 engagement with CD80/CD86 on DCs induces expression of IDO, which degrades tryptophan into kynurenine as immunoregulatory metabolites, suppressing Teff. (C) Immunosuppressive cytokine secretion: Tregs produce IL-10, IL-35, and TGF-β, which reduce inflammatory responses and inhibit Teff activation. (D) Granzyme B/perforin-mediated apoptosis: Tregs induce Teff apoptosis via granzyme B/perforin pathways and endocytotic uptake. (E) ATP-adenosine conversion: CD39 hydrolyzes extracellular ATP to AMP, and subsequently CD73 converts AMP to adenosine, which inhibits Teff responses via A2AR. (F) IL-2 deprivation mechanism via CD25high Tregs: High expression of CD25high on Tregs restricts IL-2 availability, limiting Teff expansion. A2AR; A2A receptor, CTLA4; Cytotoxic T lymphocyte-associated antigen 4, DC; dendritic cell, IDO; Indoleamine 2,3-dioxygenase, Teff; effector T cell.
Figure 1. Mechanisms of immunosuppression mediated by Tregs. Tregs suppress immune responses via multiple mechanisms and maintain tissue homeostasis. (A) CTLA4-mediated suppression: Treg-expressed CTLA-4 inhibits DC co-stimulation by reducing CD80/CD86 availability, thereby suppressing Teff activation. (B) IDO induction by DC: CTLA-4 engagement with CD80/CD86 on DCs induces expression of IDO, which degrades tryptophan into kynurenine as immunoregulatory metabolites, suppressing Teff. (C) Immunosuppressive cytokine secretion: Tregs produce IL-10, IL-35, and TGF-β, which reduce inflammatory responses and inhibit Teff activation. (D) Granzyme B/perforin-mediated apoptosis: Tregs induce Teff apoptosis via granzyme B/perforin pathways and endocytotic uptake. (E) ATP-adenosine conversion: CD39 hydrolyzes extracellular ATP to AMP, and subsequently CD73 converts AMP to adenosine, which inhibits Teff responses via A2AR. (F) IL-2 deprivation mechanism via CD25high Tregs: High expression of CD25high on Tregs restricts IL-2 availability, limiting Teff expansion. A2AR; A2A receptor, CTLA4; Cytotoxic T lymphocyte-associated antigen 4, DC; dendritic cell, IDO; Indoleamine 2,3-dioxygenase, Teff; effector T cell.CC BY · PubMed Central
Figure 2. Stage-dependent functional transition of Tregs in MASLD progression. Tregs exhibit stage-dependent functional changes throughout the progression of MASLD, shifting from hepatoprotective roles in early disease to pro-fibrotic functions in later stages. In the healthy liver, Tregs contribute to immune tolerance and tissue homeostasis. During early steatosis, these hepatoprotective and immunoregulatory functions are maintained: HSCs produce ATRA, which promotes FOXP3+ Treg development even under inflammatory conditions; M2-like KCs secrete IL-10, supporting tissue repair and Treg differentiation; and metabolic cues such as OXPHOS, ATRA derived from HSCs, SCFAs, fatty FAO, and lactate contribute to Treg differentiation and lineage stability. However, oxidative stress and lipotoxicity begin to impair Treg survival and function during this phase. In the liver, excessive lipid accumulation and insulin resistance induce hepatocyte injury, leading to a pro-inflammatory and oxidative microenvironment that induces Treg apoptosis and promotes FOXP3 degradation. Consequently, Treg lineage stability is lost, ultimately resulting in a functional imbalance between regulatory T cells and pro-inflammatory Th17 cells, which exacerbates immune dysregulation during MASLD progression. Persistent hepatocellular damage and chronic inflammation result in KC depletion and infiltration of MDMs, which partially replace the lost KCs. These infiltrating MDMs exacerbate hepatic inflammation by producing pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6. At the same time, adipose-derived IL-33 activates ST2+ PPARγ+ adipose-resident Tregs in VAT, promoting local immune regulation. As adipose tissue expands with worsening metabolic dysfunction, these VAT-Tregs decline due to increased inflammation and metabolic stress, which secondarily contributes to liver inflammation. As disease progresses, Tregs acquire a pro-fibrotic phenotype. Treg-derived TGF-β directly activates HSCs, promoting fibrogenesis. In addition, recent findings show that ATF4 expression is elevated in hepatic Tregs during fibrosis, where it enhances TGF-β activation via integrin αvβ8. Moreover, Treg-derived AREG further stimulates HSCs through EGFR signaling. These combined signals perpetuate the activation of fibrogenic pathways and accelerate the progression toward irreversible cirrhosis. AREG; amphiregulin, ATF4; activating transcription factor 4, ATRA; all-trans retinoic acid, EGRF; epidermal growth factor receptor, FAO; fatty acid oxidation, HSCs; hepatic stellate cells, IR; insulin resistance, KCs; Kupffer cells, MDMs; monocyte-derived macrophages, OXPHOS; oxidative phosphorylation, PPARγ; peroxisome proliferator-activated receptor gamma, TGF-β; transforming growth factor-beta, TNF-α; tumor necrosis factor-alpha, SCFAs; short-chain fatty acids, VAT; visceral adipose tissue.
Figure 2. Stage-dependent functional transition of Tregs in MASLD progression. Tregs exhibit stage-dependent functional changes throughout the progression of MASLD, shifting from hepatoprotective roles in early disease to pro-fibrotic functions in later stages. In the healthy liver, Tregs contribute to immune tolerance and tissue homeostasis. During early steatosis, these hepatoprotective and immunoregulatory functions are maintained: HSCs produce ATRA, which promotes FOXP3+ Treg development even under inflammatory conditions; M2-like KCs secrete IL-10, supporting tissue repair and Treg differentiation; and metabolic cues such as OXPHOS, ATRA derived from HSCs, SCFAs, fatty FAO, and lactate contribute to Treg differentiation and lineage stability. However, oxidative stress and lipotoxicity begin to impair Treg survival and function during this phase. In the liver, excessive lipid accumulation and insulin resistance induce hepatocyte injury, leading to a pro-inflammatory and oxidative microenvironment that induces Treg apoptosis and promotes FOXP3 degradation. Consequently, Treg lineage stability is lost, ultimately resulting in a functional imbalance between regulatory T cells and pro-inflammatory Th17 cells, which exacerbates immune dysregulation during MASLD progression. Persistent hepatocellular damage and chronic inflammation result in KC depletion and infiltration of MDMs, which partially replace the lost KCs. These infiltrating MDMs exacerbate hepatic inflammation by producing pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6. At the same time, adipose-derived IL-33 activates ST2+ PPARγ+ adipose-resident Tregs in VAT, promoting local immune regulation. As adipose tissue expands with worsening metabolic dysfunction, these VAT-Tregs decline due to increased inflammation and metabolic stress, which secondarily contributes to liver inflammation. As disease progresses, Tregs acquire a pro-fibrotic phenotype. Treg-derived TGF-β directly activates HSCs, promoting fibrogenesis. In addition, recent findings show that ATF4 expression is elevated in hepatic Tregs during fibrosis, where it enhances TGF-β activation via integrin αvβ8. Moreover, Treg-derived AREG further stimulates HSCs through EGFR signaling. These combined signals perpetuate the activation of fibrogenic pathways and accelerate the progression toward irreversible cirrhosis. AREG; amphiregulin, ATF4; activating transcription factor 4, ATRA; all-trans retinoic acid, EGRF; epidermal growth factor receptor, FAO; fatty acid oxidation, HSCs; hepatic stellate cells, IR; insulin resistance, KCs; Kupffer cells, MDMs; monocyte-derived macrophages, OXPHOS; oxidative phosphorylation, PPARγ; peroxisome proliferator-activated receptor gamma, TGF-β; transforming growth factor-beta, TNF-α; tumor necrosis factor-alpha, SCFAs; short-chain fatty acids, VAT; visceral adipose tissue.CC BY · PubMed Central

Verification

Claims the paper makes

36 Valid · 1 Not valid · 10 Not checked · 17 Own results and interpretations

19 more claims · 8 with their cited sources checked

Create a free account to see all 64 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 2
  • It may state two separate claims as one. 39

Create a free account to see these claims.

Citations

Cites

Show all 121 references

Cited by

See all 2

Metadata

Authors
Lee, S. E., Jo, M. G., Park, S. W., Kim, H. J., Yun, S. P., & Kim, J.-W.
Affiliations
  • Gyeongsang National University (KR)
  • Gyeongsang National University
Corresponding author
  • Yun, Seung Pil
  • Kim, Jong-Won
Venue
Animal Cells and Systems
Published
2026-02-16
Volume
30
Issue
1
Pages
250-264
ISSN
  • 1976-8354 (ISSN-L)
  • 2151-2485
OpenAlex
W7128990397
Cited by
2
References
121
Citations by year
2026: 2
FWCI
2.31
Type
journal article
Language
en
Open access
Locations
  • Animal Cells and Systems (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Research Foundation of Korea (RS-2023-00219399)
  • Ministry of Science and ICT (MSIT), Republic of Korea
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords
regulatory T cells, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, liver fibrosis, liver inflammation, hepatic stellate cell activation, immune dysregulation, metabolic stress, liver injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The double-edged sword of regulatory T cells in MASLD: from inflammation control to fibrosis promotion. https://app.cochat.ai/papers/10.1080/19768354.2026.2630463
The paper
Lee, S. E., Jo, M. G., Park, S. W., Kim, H. J., Yun, S. P., & Kim, J.-W. (2026). The double-edged sword of regulatory T cells in MASLD: from inflammation control to fibrosis promotion. Animal Cells and Systems. https://doi.org/10.1080/19768354.2026.2630463

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.